Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans.

Colizzi M, Weltens N, McGuire P, Van Oudenhove L, Bhattacharyya S.

Brain Sci. 2019 Apr 25;9(4). pii: E93. doi: 10.3390/brainsci9040093.

2.

Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis.

Colizzi M, Weltens N, McGuire P, Lythgoe D, Williams S, Van Oudenhove L, Bhattacharyya S.

Mol Psychiatry. 2019 Feb 15. doi: 10.1038/s41380-019-0374-8. [Epub ahead of print]

PMID:
30770892
3.

Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure.

Colizzi M, McGuire P, Giampietro V, Williams S, Brammer M, Bhattacharyya S.

Eur Neuropsychopharmacol. 2018 Jul;28(7):850-862. doi: 10.1016/j.euroneuro.2018.04.003. Epub 2018 Jun 21.

PMID:
29935939
4.

Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing.

Colizzi M, McGuire P, Giampietro V, Williams S, Brammer M, Bhattacharyya S.

Exp Clin Psychopharmacol. 2018 Dec;26(6):582-598. doi: 10.1037/pha0000221. Epub 2018 Aug 23.

PMID:
30138003
5.

Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis.

Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O'Carroll C, Allen P, Seal ML, Fletcher PC, Crippa JA, Giampietro V, Mechelli A, Atakan Z, McGuire P.

Arch Gen Psychiatry. 2009 Apr;66(4):442-51. doi: 10.1001/archgenpsychiatry.2009.17.

PMID:
19349314
6.

Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.

D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J.

Neuropsychopharmacology. 2008 Sep;33(10):2505-16. doi: 10.1038/sj.npp.1301643. Epub 2008 Jan 9.

7.

The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans.

Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, D'Souza DC.

Biol Psychiatry. 2015 Dec 1;78(11):805-13. doi: 10.1016/j.biopsych.2015.03.023. Epub 2015 Mar 30.

8.

Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis.

Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Malhi S, Giampietro V, Williams S, Brammer M, Rubia K, Collier DA, McGuire PK.

Eur Neuropsychopharmacol. 2015 Jan;25(1):26-37. doi: 10.1016/j.euroneuro.2014.11.018. Epub 2014 Dec 4.

PMID:
25532865
9.

Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC.

Bhattacharyya S, Sainsbury T, Allen P, Nosarti C, Atakan Z, Giampietro V, Brammer M, McGuire PK.

Psychol Med. 2018 Dec;48(16):2748-2756. doi: 10.1017/S0033291718000387. Epub 2018 Mar 5.

PMID:
29502548
10.

Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.

Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM.

Eur Neuropsychopharmacol. 2008 Aug;18(8):569-77. doi: 10.1016/j.euroneuro.2008.04.008. Epub 2008 Jun 10.

PMID:
18544469
11.

The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.

Englund A, Atakan Z, Kralj A, Tunstall N, Murray R, Morrison P.

J Psychopharmacol. 2016 Feb;30(2):140-51. doi: 10.1177/0269881115615104. Epub 2015 Nov 17.

PMID:
26577065
12.

Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.

Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV.

Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34. doi: 10.1016/j.euroneuro.2014.11.014. Epub 2014 Dec 5.

13.

Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O'Carrol C, Atakan Z, Zuardi AW, McGuire PK.

Arch Gen Psychiatry. 2009 Jan;66(1):95-105. doi: 10.1001/archgenpsychiatry.2008.519.

PMID:
19124693
14.

Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.

Müller-Vahl KR, Koblenz A, Jöbges M, Kolbe H, Emrich HM, Schneider U.

Pharmacopsychiatry. 2001 Jan;34(1):19-24.

PMID:
11229617
15.
16.

The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.

Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM.

Psychol Med. 2009 Oct;39(10):1607-16. doi: 10.1017/S0033291709005522. Epub 2009 Apr 1.

PMID:
19335936
17.

Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.

Juckel G, Roser P, Nadulski T, Stadelmann AM, Gallinat J.

Schizophr Res. 2007 Dec;97(1-3):109-17. Epub 2007 Sep 19.

PMID:
17884351
18.

Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers.

Atakan Z, Bhattacharyya S, Allen P, Martín-Santos R, Crippa JA, Borgwardt SJ, Fusar-Poli P, Seal M, Sallis H, Stahl D, Zuardi AW, Rubia K, McGuire P.

Psychol Med. 2013 Jun;43(6):1255-67. doi: 10.1017/S0033291712001924. Epub 2012 Oct 1.

PMID:
23020923
19.
20.

Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing.

Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, Rubia K, Kambeitz J, O'Carroll C, Seal ML, Giampietro V, Brammer M, Zuardi AW, Atakan Z, McGuire PK.

Arch Gen Psychiatry. 2012 Jan;69(1):27-36. doi: 10.1001/archgenpsychiatry.2011.161.

PMID:
22213786

Supplemental Content

Support Center